Pleural Effusion, Malignant
Conditions
Brief summary
Malignant Pleural Effusion (MPE) is a collection of fluid inside the chest caused by cancer. It is a common medical problem and often causes severe breathlessness. Patients with this condition generally have a very poor survival and so it is extremely important that they are given effective treatment as soon as possible to minimise the amount of time they have to spend in hospital. Standard treatment for MPE involves an admission to hospital to drain the fluid and then attempt to prevent the fluid from returning by sticking the lung to the inside of the rib cage with medical talc powder which acts like glue. This is called talc pleurodesis (TP) but unfortunately it fails in about 30% of patients. This is usually because the lung has not fully re-expanded and has not made contact with the inside of the ribs. When this happens, the fluid can be effectively treated with a different type of drainage tube called an indwelling pleural catheter (IPC) which tunnels under the skin and is drained at home by the district nurses. It is thought that pressure measurements taken from the fluid as it is drained may be able to show doctors whether or not the lung will re-expand before patients are committed to either TP or an IPC. In this research we wish to test if these measurements can be used to choose which is the best first treatment option (TP or IPC) for patients with MPE. We have called this 'EDIT management'. Since it is uncertain whether this new approach will work, patients will be randomised to have either standard treatment or EDIT management. We will compare the two groups to assess whether the patients who had EDIT management had to have fewer repeat procedures over the following 3 months.
Interventions
PROCEDUREEDIT Management
EDIT management 1. Volumetric Pleural MRI for pre-aspiration pleural cavity volume 2. Large volume pleural aspiration with recording of intra-pleural pressure during aspiration 3. Volumetric Pleural MRI for post-aspiration pleural cavity volume 4. Computation of PEL250, defined as the rolling average of pleural elastance over the preceding 250ml aspirated. MaxPEL250 ≥ 14.5 cm H2O/L: allocated to 1st-line IPC MaxPEL250 \< 14.5 cm H2O/L: allocated to 1st-line TP 5. EDIT-directed 1st-line treatment to be delivered within 24 hours; if insufficient residual pleural fluid to allow standard Seldinger insertion technique then Boutin-type needle used for pneumothorax induction and guide wire insertion.
PROCEDUREChest drain and talc pleurodesis
Intercostal chest drain insertion and talc slurry instillation according to British Thoracic Society guidelines
Sponsors
Rocket Medical plc
NHS Greater Glasgow and Clyde
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Clinically confident diagnosis of malignant pleural effusion, defined as any of the following: 1. Pleural effusion with histocytologically proven pleural malignancy OR 2. Pleural effusion in the context of histocytologically proven malignancy elsewhere, without a clear alternative cause for fluid OR 3. Pleural effusion with typical features of malignancy with pleural involvement on cross-sectional imaging (CT/MRI) * Degree of breathlessness for which therapeutic pleural intervention would be offered * Age \>18 years * Expected survival \> 3 months * Written Informed Consent
Exclusion criteria
* Females who are pregnant or lactating * Clinical suspicion of non-expansile lung for which talc pleurodesis would not be offered * Patient preference for 1st-line indwelling pleural catheter (IPC) insertion * Previous ipsilateral failed talc pleurodesis * Estimated pleural fluid volume ≤ 1 litre, as defined by thoracic ultrasound * Any contraindication to chest drain or IPC insertion, including: Irreversible coagulopathy Inaccessible pleural collection, including lack of suitable IPC tunnel site \- Any contraindication to MRI scanning, including: Claustrophobia Cardiac pacemaker Ferrous metal implants or retained ferrous metal foreign body Previously documented reaction to Gadolinium-containing intravenous contrast agent Significant renal impairment (eGFR\<30 ml/min)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility of recruiting 30 patients within 12 months and randomising them to either EDIT Management or Standard Care | 12 months | The number of patients recruited and randomised within 12 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of adverse events associated with the manometry procedure | 12 months | Number of participants with Adverse Events (AEs) and Serious AEs (SAEs), defined by United Kingdom Good Clinical Practice in Research, associated with use of the digital pleural manometer |
| Aspiration threshold to detect abnormal pleural elastance | 12 months | The pleural fluid aspiration volume at which the rolling average pleural elastance over the preceding 250ml (PEL250) first exceeds the upper limit of normal (14.5cm H2O/L). |
| Failure rate of the manometry procedure | 12 months | Defined as the proportion of patients in whom PEL cannot be computed |
| Assess accuracy of pleural cavity volume change assumptions | 12 months | To test the assumption that pleural cavity volume change is equivalent to the volume of pleural fluid removed during aspiration by measuring: 1. Pleural fluid aspiration volume 2. Pleural cavity volume change, as measured directly using volumetric Magnetic Resonance Imaging (MRI), calculated as pre- minus post-aspiration pleural cavity volume |
| Assess accuracy of ultrasound effusion volume estimate | 12 months | To test the accuracy of a predictive model of pleural effusion volume based on thoracic ultrasound measurements by measuring: 1. Thoracic ultrasound estimated total pleural effusion volume 2. Pre-pleural fluid aspiration pleural cavity volume measured by volumetric MRI |
| Proportion of patients requiring pneumothorax induction following manometry | 12 months | The proportion of patients in which pneumothorax induction is required to facilitate safe intercostal chest drain/IPC insertion in the EDIT arm (Group A) |
Countries
United Kingdom
Contacts
Primary ContactJoanne McGarry
Outcome results
None listed